The big O. The climax. The explosive finale. For men, this almost always involves ejaculation. But guys, have you ever wondered how much semen you’re actually meant to produce when you orgasm? It’s a ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) agreed to acquire Exact ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Abbott Laboratories, NYSE:ABT, is repositioning its ...

Recent Exact Sciences Corporation financials show accelerating revenue growth and stable margins, despite ongoing investments in screening and MRD. While EXAS maintains leadership in stool-based CRC ...

Being a life sciences CEO is not for the faint of heart. Drug discovery and patent approvals are costly and time-consuming, and even if an executive can steer a company to clinical trials, there’s a ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott Laboratories ABT-0.97%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS-0.07%decrease; red down pointing triangle in a deal valued at about ...